{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:12:43Z","timestamp":1790118763388,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202006010035"],"award-info":[{"award-number":["202006010035"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01527-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:14:09Z","timestamp":1748920449000},"page":"1165-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Population Pharmacokinetic Analysis for Piperacillin\/Tazobactam in Patients with End-Stage Kidney Disease Undergoing Intermittent Haemodialysis: Extension of a General-Purpose Model"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4998-430X","authenticated-orcid":false,"given":"D.","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-3998","authenticated-orcid":false,"given":"J. V.","family":"Koomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vanommeslaeghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Delanghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-5539","authenticated-orcid":false,"given":"P. J.","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-1743","authenticated-orcid":false,"given":"S.","family":"Eloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"1527_CR1","unstructured":"FDA label ZOSYN\u00ae (piperacillin and tazobactam) for injection, for intravenous use 2017 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf, accessed on: 22-04-2025]"},{"key":"1527_CR2","unstructured":"EMA label Tazocin and associated names (piperacillin and tazobactam, 2\/0.25 g and 4\/0.5 g powder for solution for infusion) 2013 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/tazocin-article-30-referral-annex-iii_en.pdf, accessed on: 22-04-2025]"},{"issue":"12","key":"1527_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/j.1552-4604.1994.tb04733.x","volume":"34","author":"CE Halstenson","year":"1994","unstructured":"Halstenson CE, Wong MO, Johnson CA, Zimmerman SW, Onorato JJ, Keane WF, et al. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin\/tazobactam in subjects with renal impairment. J Clin Pharmacol. 1994;34(12):1208\u201317.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1527_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/clpt.1992.5","volume":"51","author":"CA Johnson","year":"1992","unstructured":"Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther. 1992;51(1):32\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1527_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01579-23","volume":"68","author":"JQ Hudson","year":"2024","unstructured":"Hudson JQ, Hilgers MN, Gosmanova EO. Removal of common antimicrobial agents by sustained low-efficiency dialysis. Antimicrob Agents Chemother. 2024;68(3): e0157923.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1527_CR6","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/jac\/dky057","volume":"73","author":"MG Sinnollareddy","year":"2018","unstructured":"Sinnollareddy MG, Roberts MS, Lipman J, Peake SL, Roberts JA. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J Antimicrob Chemother. 2018;73(6):1647\u201350.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1527_CR7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40262-024-01397-w","volume":"63","author":"F Ferrari","year":"2024","unstructured":"Ferrari F, Milla P, Sartori M, Zanza C, Tesauro M, Longhitano Y, et al. Antibiotics removal during continuous renal replacement therapy in septic shock patients: mixed modality versus \u201cexpanded haemodialysis.\u201d Clin Pharmacokinet. 2024;63(8):1167\u201376.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1527_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40262-024-01460-6","volume":"64","author":"D Kong","year":"2025","unstructured":"Kong D, Roberts JA, Lipman J, Taccone FS, Cohen-Wolkowiez M, Sime FB, et al. A pooled pharmacokinetic analysis for piperacillin\/tazobactam across different patient populations: from premature infants to the elderly. Clin Pharmacokinet. 2025;64(1):107\u201326.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1527_CR9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/ki.1996.534","volume":"50","author":"JE Tattersall","year":"1996","unstructured":"Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The post-hemodialysis rebound: predicting and quantifying its effect on Kt\/V. Kidney Int. 1996;50(6):2094\u2013102.","journal-title":"Kidney Int"},{"issue":"2","key":"1527_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"1527_CR11","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1128\/AAC.41.8.1636","volume":"41","author":"JF Westphal","year":"1997","unstructured":"Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, et al. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother. 1997;41(8):1636\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1527_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11095-020-02832-w","volume":"37","author":"A Broeker","year":"2020","unstructured":"Broeker A, Vossen MG, Thalhammer F, Wallis SC, Lipman J, Roberts JA, et al. An integrated dialysis pharmacometric (IDP) model to evaluate the pharmacokinetics in patients undergoing renal replacement therapy. Pharm Res. 2020;37(6):96.","journal-title":"Pharm Res"},{"issue":"3","key":"1527_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106058","volume":"56","author":"CJP Economou","year":"2020","unstructured":"Economou CJP, Ordonez J, Wallis SC, Richards B, McWhinney B, Lipman J, et al. Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. Int J Antimicrob Agents. 2020;56(3): 106058.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1527_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/psp4.13180","volume":"13","author":"CJ O\u2019Hanlon","year":"2024","unstructured":"O\u2019Hanlon CJ, Holford N, Anderson BJ, Greaves M, Blackburn L, Tingle MD, et al. A pharmacokinetic framework describing antibiotic adsorption to cardiopulmonary bypass devices. CPT Pharmacometrics Syst Pharmacol. 2024;13(8):1409\u201321.","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01527-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:16:38Z","timestamp":1757178998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01527-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01527-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"8 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by departmental funding and China Scholarship Council to Daming Kong (202006010035).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kong D. and Koomen J.V. certify that they have no affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in the manuscript. Over the last 3 years Colin P.J. and his research group have been involved in contract research for PAION UK Ltd. (London, England) and Acacia Pharma Ltd. (Cambridge, England).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Eloot S. and Van Biesen W. contributed to the clinical study conception and design. Kong D., Koomen J.V., and Colin P.J. contributed to the pharmacokinetic modelling conception and design. Patient inclusion and data collection were performed by Eloot S., Vanommeslaeghe F., and Delanghe S. Data handling was performed by Eloot S., while data analysis (pharmacokinetics modelling) was performed by Kong D. Kong D. and Koomen J.V. wrote the first draft of the manuscript. All authors reviewed and edited previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data will be made available upon reasonable request to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability Statement"}},{"value":"The study was approved by the independent Ethics Committee of the Ghent University Hospital (2016\/0973 \u2013 B670201629362) and was registered on ClinicalTrials.gov (NCT03909698 \u2013 \u201cAntibiotic Dosing in Patients on Intermittent Haemodialysis\u201d). Written informed consent was obtained from all patients prior to enrolment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval\/Consent to Participate\/Consent for Publication"}},{"value":"The NONMEM code for the final piperacillin (PIP)\/tazobactam (TAZ) population pharmacokinetic model is available in the electronic supplemental materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}